|
**Overview**: Pneumoslide IgM IFA Panel**Introduction**: The Pneumoslide IgM IFA Panel is a diagnostic tool designed to screen for respiratory infections using serum samples. In India, atypical/community-acquired pneumonia from influenza A/B, RSV, adenovirus, mycoplasma, chlamydia, parainfluenza, and legionella contributes to ~20-40 percent of cases, especially in children/elderly during monsoon/winter. High morbidity from under-testing in rural/low-SES patients with persistent cough/fever, limited serology labs, delayed macrolide/oseltamivir leading to prolonged illness or complications. Per microbiology practices aligned with ICMR and National Centre for Disease Control guidelines, the test employs IFA for IgM against 8 respiratory pathogens over 1-2 days with high specificity, valuable for rapid atypical pathogen identification. This diagnostic falls under infection screening and targets patients with atypical pneumonia or outbreak suspicion, addressing accurate detection to guide targeted antimicrobials. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise respiratory pathogen screening and reducing pneumonia burden. Its serum-based approach ensures reliable IgM detection.**Other Names**: Pneumoslide Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/immunology, compliant with 2025 standards.**Historical Milestone**: Multi-pathogen IFA panel standard; in India, used in respiratory surveillance.**Purpose**: The test assesses 8 parameters including influenza A IgM to guide respiratory infection screening, detect atypical pathogens, inform antimicrobials.**Test Parameters**: 1. Influenza A IgM, 2. Influenza B IgM, 3. RSV IgM, 4. Adenovirus IgM, 5. Mycoplasma IgM, 6. Chlamydia IgM, 7. Parainfluenza IgM, 8. Legionella IgM.**Pretest Condition**: No fasting required; patients should have respiratory symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cough, fever, season.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected pathogen including complications, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using IFA by trained personnel to ensure sterile technique, avoid artifacts, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or early sampling can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM indicates acute infection, necessitating specialist input.**Specialist Consultation**: Pulmonologists or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: PCR panel, chest X-ray for confirmation.**Test Limitations**: IgM may persist/cross-react; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Respiratory Studies India 2023. |
